NASDAQ:HEPA Hepion Pharmaceuticals Q2 2026 Earnings Report $0.10 -0.01 (-5.00%) As of 09:52 AM Eastern ProfileEarnings History Hepion Pharmaceuticals EPS ResultsActual EPS-$0.08Consensus EPS -$200.00Beat/MissBeat by +$199.92One Year Ago EPSN/AHepion Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHepion Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time7:00AM ETUpcoming EarningsHepion Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, October 14, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Hepion Pharmaceuticals Earnings HeadlinesHepion Pharmaceuticals Expands Authorized Share Capital for Growth2 hours ago | tipranks.comHepion Pharmaceuticals Announces New Private Placement FinancingAugust 4, 2026 | tipranks.comElon’s "infinite money glitch"James Altucher called Facebook's $100 billion valuation in 2007, predicted Apple's run to a trillion, and flagged Netflix early. Now he's focused on three words from Elon Musk: infinite money glitch. Musk used the phrase to describe a new class of technology he says could reshape markets. Altucher believes it could rank among the biggest wealth events of our lifetime.October 2 at 1:00 AM | Paradigm Press (Ad)Hepion Shareholders Expand Equity Plan at 2026 MeetingJune 17, 2026 | tipranks.comHepion Pharmaceuticals Announces Private Placement Financing AgreementApril 22, 2026 | tipranks.comHepion Finalizes CEO Separation Agreement Amid Leadership TransitionApril 14, 2026 | tipranks.comSee More Hepion Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hepion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hepion Pharmaceuticals and other key companies, straight to your email. Email Address About Hepion PharmaceuticalsHepion Pharmaceuticals (NASDAQ:HEPA) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases. Its research has centered on conditions including metabolic dysfunction-associated steatohepatitis (MASH), hepatitis B virus infection, and liver cancer. The company’s lead investigational product is rencofilstat, an oral pan-cyclophilin inhibitor designed to address multiple disease mechanisms involved in liver injury and fibrosis. Hepion has evaluated the compound in clinical studies involving patients with chronic liver disease and has also investigated its potential use in combination with other therapies. Hepion was formerly known as ContraVir Pharmaceuticals and adopted the Hepion name as its strategy became more focused on liver disease. The company has been based in the United States and has conducted development activities through clinical research programs rather than commercial product sales. Robert Foster, a scientist and biotechnology executive, has historically served as the company’s chief executive officer and president.View Hepion Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market ShareCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
